378 related articles for article (PubMed ID: 29023170)
1. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives.
Di Bonaventura C; Labate A; Maschio M; Meletti S; Russo E
Expert Opin Pharmacother; 2017 Nov; 18(16):1751-1764. PubMed ID: 29023170
[TBL] [Abstract][Full Text] [Related]
2. The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy.
Twele F; Bankstahl M; Klein S; Römermann K; Löscher W
Neuropharmacology; 2015 Aug; 95():234-42. PubMed ID: 25839899
[TBL] [Abstract][Full Text] [Related]
3. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy.
Rohracher A; Brigo F; Höfler J; Kalss G; Neuray C; Dobesberger J; Kuchukhidze G; Leitinger M; Trinka E
Expert Opin Pharmacother; 2016 Jul; 17(10):1403-11. PubMed ID: 27267634
[TBL] [Abstract][Full Text] [Related]
4. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.
Strzelczyk A; Willems LM; Willig S; Rosenow F; Bauer S
Expert Rev Clin Pharmacol; 2015; 8(6):733-40. PubMed ID: 26436331
[TBL] [Abstract][Full Text] [Related]
5. Perampanel: Does it have broad-spectrum potential?
Potschka H; Trinka E
Epilepsia; 2019 Mar; 60 Suppl 1():22-36. PubMed ID: 29953584
[TBL] [Abstract][Full Text] [Related]
6. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.
Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM
J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316
[TBL] [Abstract][Full Text] [Related]
7. The AMPA receptor antagonist perampanel is a new hope in the treatment for epilepsy.
El Desoky ES
Fundam Clin Pharmacol; 2014 Oct; 28(5):473-80. PubMed ID: 24750493
[TBL] [Abstract][Full Text] [Related]
8. The discovery and development of perampanel for the treatment of epilepsy.
Hanada T
Expert Opin Drug Discov; 2014 Apr; 9(4):449-58. PubMed ID: 24559052
[TBL] [Abstract][Full Text] [Related]
9. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.
Rohracher A; Höfler J; Kalss G; Leitinger M; Kuchukhidze G; Deak I; Dobesberger J; Novak H; Pilz G; Zerbs A; Trinka E
Epilepsy Behav; 2015 Aug; 49():354-8. PubMed ID: 25962657
[TBL] [Abstract][Full Text] [Related]
10. Introduction: Perampanel--new mode of action and new option for patients with epilepsy.
Steinhoff BJ
Epilepsia; 2014 Jan; 55 Suppl 1():1-2. PubMed ID: 24400689
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the pharmacotherapy of epilepsy: brivaracetam and perampanel as broad-spectrum antiseizure drugs for the treatment of epilepsies and status epilepticus.
Willems LM; Bauer S; Rosenow F; Strzelczyk A
Expert Opin Pharmacother; 2019 Oct; 20(14):1755-1765. PubMed ID: 31264486
[No Abstract] [Full Text] [Related]
12. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
[No Abstract] [Full Text] [Related]
13. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel.
Zaccara G; Giovannelli F; Cincotta M; Iudice A
Expert Rev Neurother; 2013 Jun; 13(6):647-55. PubMed ID: 23739002
[TBL] [Abstract][Full Text] [Related]
14. Development of perampanel in epilepsy.
Satlin A; Kramer LD; Laurenza A
Acta Neurol Scand Suppl; 2013; (197):3-8. PubMed ID: 23480150
[TBL] [Abstract][Full Text] [Related]
15. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.
Rektor I
Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931
[TBL] [Abstract][Full Text] [Related]
16. Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy.
Citraro R; Aiello R; Franco V; De Sarro G; Russo E
Expert Opin Ther Targets; 2014 Mar; 18(3):319-34. PubMed ID: 24387310
[TBL] [Abstract][Full Text] [Related]
17. Electro-clinical analysis of epilepsy patients with generalized seizures on adjunctive perampanel treatment.
Montoya Gutiérrez FJ; Díaz Román M; Cerveró Albert D
Epilepsy Res; 2020 Sep; 165():106378. PubMed ID: 32622260
[TBL] [Abstract][Full Text] [Related]
18. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A
Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
[TBL] [Abstract][Full Text] [Related]
20. [Perampanel in the treatment of patients with epilepsy].
Rider FK
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9. Vyp. 2):63-69. PubMed ID: 29213041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
